Suppr超能文献

硫唑嘌呤与5-氨基水杨酸治疗激素依赖型溃疡性结肠炎的随机对照试验

Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis.

作者信息

Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G

机构信息

Cattedra di Gastroenterologia, Azienda Ospedaliera "L Sacco", Polo Universitario, Via G.B. Grassi 74, 20157 Milano, Italy.

出版信息

Gut. 2006 Jan;55(1):47-53. doi: 10.1136/gut.2005.068809. Epub 2005 Jun 21.

Abstract

BACKGROUND AND AIMS

There are limited evidence based data concerning the use of azathioprine in ulcerative colitis. We aimed to compare the efficacy of azathioprine and oral 5-aminosalicylic acid in inducing remission of steroid dependent ulcerative colitis.

METHODS

Seventy two patients with steroid dependent ulcerative colitis were admitted to this investigator-blind study. Steroid dependence was defined as a requirement for steroid therapy > or =10 mg/day during the preceding six months, with at least two attempts to discontinue the medication. The disease had to be clinically and endoscopically active at study entry, and all patients were taking systemic prednisolone (40 mg/day). Patients were randomised to receive azathioprine 2 mg/kg/day or oral 5-aminosalicylic acid 3.2 g/day, for a six month follow up period. The outcome of the treatment was defined as (1) success, indicating induction of clinical and endoscopic remission and steroid discontinuation, or (2) failure, indicating the absence of clinical and endoscopic remission and therefore the need for at least one further cycle of systemic steroids to control symptoms, apart from the initial one, or colectomy.

RESULTS

Significantly more patients in the azathioprine than in the 5-aminosalicylic acid group had clinical and endoscopic remission, and discontinued steroid therapy, both in the intention to treat (azathioprine v 5-aminosalicylic acid: 19/36 patients (53%) v 7/36 (21%); odds ratio (OR) 4.78 (95% confidence interval (CI) 1.57-14.5)) and per protocol (azathioprine v 5-aminosalicylic acid: 19/33 patients (58%) v 7/34 (21%); OR 5.26 (95% CI 1.59-18.1)) analysis.

CONCLUSIONS

Azathioprine is significantly more effective than 5-aminosalicylic acid in inducing clinical and endoscopic remission and avoiding steroid requirement in the treatment of steroid dependent ulcerative colitis.

摘要

背景与目的

关于硫唑嘌呤在溃疡性结肠炎中的应用,基于证据的数据有限。我们旨在比较硫唑嘌呤和口服5-氨基水杨酸诱导激素依赖型溃疡性结肠炎缓解的疗效。

方法

72例激素依赖型溃疡性结肠炎患者被纳入这项研究者设盲的研究。激素依赖定义为在过去6个月内需要≥10mg/天的激素治疗,且至少有两次尝试停药。在研究开始时,疾病必须在临床和内镜下处于活动期,所有患者均服用系统性泼尼松龙(40mg/天)。患者被随机分为接受2mg/kg/天硫唑嘌呤或3.2g/天口服5-氨基水杨酸治疗,随访6个月。治疗结果定义为:(1)成功,即诱导临床和内镜缓解并停用激素;(2)失败,即未出现临床和内镜缓解,因此除初始疗程外,需要至少一个额外的系统性激素疗程来控制症状,或进行结肠切除术。

结果

在意向性分析(硫唑嘌呤组与5-氨基水杨酸组:19/36例患者(53%)对7/36例(21%);优势比(OR)4.78(95%置信区间(CI)1.57 - 14.5))和符合方案分析(硫唑嘌呤组与5-氨基水杨酸组:19/33例患者(58%)对7/34例(21%);OR 5.26(95%CI 1.59 - 18.1))中,硫唑嘌呤组临床和内镜缓解且停用激素的患者显著多于5-氨基水杨酸组。

结论

在激素依赖型溃疡性结肠炎治疗中,硫唑嘌呤在诱导临床和内镜缓解以及避免激素需求方面显著优于5-氨基水杨酸。

相似文献

6
MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
Aliment Pharmacol Ther. 2008 Jun 1;27(11):1094-102. doi: 10.1111/j.1365-2036.2008.03688.x. Epub 2008 Mar 22.
7
The long-term efficacy of azathioprine in steroid-dependent ulcerative colitis.
Scand J Gastroenterol. 2013 Dec;48(12):1386-93. doi: 10.3109/00365521.2013.845908. Epub 2013 Oct 28.
10
Oral methotrexate in ulcerative colitis.
Aliment Pharmacol Ther. 2005 Feb 15;21(4):385-9. doi: 10.1111/j.1365-2036.2005.02331.x.

引用本文的文献

1
Perspectives in clinical research on Azathioprine for steroid-dependent ulcerative colitis.
Front Med (Lausanne). 2025 Mar 25;12:1551906. doi: 10.3389/fmed.2025.1551906. eCollection 2025.
2
Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis.
Cochrane Database Syst Rev. 2025 Feb 27;2(2):CD000478. doi: 10.1002/14651858.CD000478.pub5.
3
Probiotic Microorganisms in Inflammatory Bowel Diseases: Live Biotherapeutics as Food.
Foods. 2024 Dec 18;13(24):4097. doi: 10.3390/foods13244097.
4
AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis.
Gastroenterology. 2024 Dec;167(7):1307-1343. doi: 10.1053/j.gastro.2024.10.001.
5
Deep mucosal healing in ulcerative colitis: how deep is better?
Front Med (Lausanne). 2024 Aug 2;11:1429427. doi: 10.3389/fmed.2024.1429427. eCollection 2024.
9
Effectiveness of Mesalamine in Patients With Ulcerative Colitis: A Systematic Review.
Cureus. 2023 Aug 24;15(8):e44055. doi: 10.7759/cureus.44055. eCollection 2023 Aug.
10
Personalize, participate, predict, and prevent: 4Ps in inflammatory bowel disease.
Front Med (Lausanne). 2023 Apr 11;10:1031998. doi: 10.3389/fmed.2023.1031998. eCollection 2023.

本文引用的文献

2
Infliximab maintenance therapy for fistulizing Crohn's disease.
N Engl J Med. 2004 Feb 26;350(9):876-85. doi: 10.1056/NEJMoa030815.
3
Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis.
Gastroenterology. 2003 Oct;125(4):1025-31. doi: 10.1016/s0016-5085(03)01214-9.
4
THE COURSE AND PROGNOSIS OF ULCERATIVE COLITIS.
Gut. 1963 Dec;4(4):299-315. doi: 10.1136/gut.4.4.299.
5
VARIATION BETWEEN OBSERVERS IN DESCRIBING MUCOSAL APPEARANCES IN PROCTOCOLITIS.
Br Med J. 1964 Jan 11;1(5375):89-92. doi: 10.1136/bmj.1.5375.89.
8
Infliximab for treatment of steroid-refractory ulcerative colitis.
Dig Liver Dis. 2002 Sep;34(9):631-4. doi: 10.1016/s1590-8658(02)80205-5.
10
Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis.
Am J Gastroenterol. 2002 Oct;97(10):2577-84. doi: 10.1111/j.1572-0241.2002.06026.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验